JP2017507963A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507963A5
JP2017507963A5 JP2016556821A JP2016556821A JP2017507963A5 JP 2017507963 A5 JP2017507963 A5 JP 2017507963A5 JP 2016556821 A JP2016556821 A JP 2016556821A JP 2016556821 A JP2016556821 A JP 2016556821A JP 2017507963 A5 JP2017507963 A5 JP 2017507963A5
Authority
JP
Japan
Prior art keywords
cancer
combination
amino
chloro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016556821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/051380 external-priority patent/WO2015136398A1/en
Publication of JP2017507963A publication Critical patent/JP2017507963A/ja
Publication of JP2017507963A5 publication Critical patent/JP2017507963A5/ja
Pending legal-status Critical Current

Links

JP2016556821A 2014-03-12 2015-02-24 Btk阻害薬とakt阻害薬を含む組み合わせ Pending JP2017507963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461951640P 2014-03-12 2014-03-12
US61/951,640 2014-03-12
PCT/IB2015/051380 WO2015136398A1 (en) 2014-03-12 2015-02-24 Combination comprising a btk inhibitor and an akt inhibitor

Publications (2)

Publication Number Publication Date
JP2017507963A JP2017507963A (ja) 2017-03-23
JP2017507963A5 true JP2017507963A5 (cg-RX-API-DMAC7.html) 2018-04-05

Family

ID=52630445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016556821A Pending JP2017507963A (ja) 2014-03-12 2015-02-24 Btk阻害薬とakt阻害薬を含む組み合わせ

Country Status (10)

Country Link
US (2) US20170020878A1 (cg-RX-API-DMAC7.html)
EP (1) EP3116546A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017507963A (cg-RX-API-DMAC7.html)
KR (1) KR20160127754A (cg-RX-API-DMAC7.html)
CN (1) CN106456642A (cg-RX-API-DMAC7.html)
AU (1) AU2015228475B9 (cg-RX-API-DMAC7.html)
CA (1) CA2942204A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016011674A (cg-RX-API-DMAC7.html)
RU (1) RU2016139697A (cg-RX-API-DMAC7.html)
WO (1) WO2015136398A1 (cg-RX-API-DMAC7.html)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
ES2590491T3 (es) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
WO2013010869A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ, インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
CA2852964A1 (en) 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Bicyclic piperazine compounds
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2013161848A1 (ja) 2012-04-27 2013-10-31 カルナバイオサイエンス株式会社 新規1,2,4-トリアジン誘導体
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶

Similar Documents

Publication Publication Date Title
JP2016528162A5 (cg-RX-API-DMAC7.html)
JP2012193216A5 (cg-RX-API-DMAC7.html)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
JP2016503399A5 (cg-RX-API-DMAC7.html)
JP2018505193A5 (cg-RX-API-DMAC7.html)
JP2017530983A5 (cg-RX-API-DMAC7.html)
JP2015536964A5 (cg-RX-API-DMAC7.html)
JP2015523397A5 (cg-RX-API-DMAC7.html)
JP2011126896A5 (cg-RX-API-DMAC7.html)
JP2014528464A5 (cg-RX-API-DMAC7.html)
JP2015524472A5 (cg-RX-API-DMAC7.html)
JP2014507412A5 (cg-RX-API-DMAC7.html)
RU2017102319A (ru) Прерывистое введение ингибитора mdm2
JP2018168191A5 (cg-RX-API-DMAC7.html)
JP2015038135A5 (cg-RX-API-DMAC7.html)
JP2015536986A5 (cg-RX-API-DMAC7.html)
HRP20120918T1 (hr) Aminopirazolski spoj
RU2016116789A (ru) Комбинация энзалутамида и афурезертиба для лечения рака
RU2015119218A (ru) Комбинация
JP2015503579A5 (cg-RX-API-DMAC7.html)
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
JP2015517523A5 (cg-RX-API-DMAC7.html)
JP2022506829A5 (cg-RX-API-DMAC7.html)
JP2015508765A5 (cg-RX-API-DMAC7.html)
JP2013536243A5 (cg-RX-API-DMAC7.html)